FDA grants Fast Track to SOT109, an ADC targeting CDH17 for advanced colorectal cancer
The U.S. Food and Drug Administration has granted Fast Track Designation to SOTIO Biotech’s investigational antibody‑drug conjugate SOT109, which targets…
If seniors regularly take part in culturally relevant activities, their bodies look about three years younger
A study of 1,899 adults aged 50 and older found that those who regularly attended cultural events or took part…
If you eat chili peppers often: when a meta-analysis links very high intake to higher esophageal cancer risk
A recent systematic review and meta-analysis of 14 observational studies (over 11,000 participants and more than 5,000 gastrointestinal cancer cases)…
Yale finds a BC6-led electrical network in the retina that amplifies weak visual signals
Yale neuroscientists report that bipolar cells in the retina are not strictly independent; instead, a hierarchy of electrical synapses lets…
Denecimig’s sustained safety and flexible weekly–to–monthly dosing in FRONTIER4 support its role as a next‑generation prophylactic for hemophilia A
Interim results from the phase 3 FRONTIER4 extension show Novo Nordisk’s denecimig (Mim8) provided low bleeding rates and a favorable…
AHA 2026: Porphyromonas gingivalis from gum disease tied to inflammation and calcification in early CAVS research
Preliminary research presented at the American Heart Association’s 2026 Basic Cardiovascular Sciences Scientific Sessions links the periodontal bacterium Porphyromonas gingivalis…
When Mild Insomnia Responds: Lactucin‑Rich Lettuce Extracts Increased Sleep Time in Korean Trials
Clinical trials in South Korea found that supplements derived from Heukharang (a lactucin-rich lettuce cultivar) and lettuce seed oil produced…
UBC Okanagan mapped the enzymes that make mitraphylline — but that doesn’t mean a drug or mass supply is imminent
UBC Okanagan researchers have identified the two plant enzymes that assemble mitraphylline’s distinctive spirooxindole architecture, a necessary first step toward…
With FDA Fast Track, Coya’s COYA 302 advances to a make-or-break Phase 2 readout expected in early 2027
Coya Therapeutics’ investigational ALS therapy COYA 302 has been granted FDA Fast Track designation while the randomized, double‑blind ALSTARS Phase…
When optimism bias meets viral nutrition claims: pick a starting point that won’t backfire
People commonly rate their own diets as healthier than they are — a mental shortcut called optimism bias — and…